Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colleen Annesley

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Transplantation and Cellular Therapy|October 2, 2025
Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell ProvidersKevin O McNerney, Caroline Diorio, Colleen Annesley, et al.
Blood Advances|August 12, 2024
Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALLColleen Annesley, Adam Lamble, Corinne Summers, et al.
Blood|November 8, 2019
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyRebecca A Gardner, Francesco Ceppi, Julie Rivers, et al.
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Blood|November 19, 2024
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaMonica S Nair, Sara K Silbert, Kai Rejeski, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Blood|April 15, 2017
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsRebecca A Gardner, Olivia Finney, Colleen Annesley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) StudyTodd M Cooper, Jeannette Cassar, Elena Eckroth, et al.
Blood|April 15, 2025
Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALLColleen Annesley, Kristy D Seidel, Qian Wu, et al.
Cancer Immunology Research|May 17, 2022
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult SubjectsFrancesco Ceppi, Ashley L Wilson, Colleen Annesley, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Transplantation and Cellular Therapy|October 2, 2025
Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell ProvidersKevin O McNerney, Caroline Diorio, Colleen Annesley, et al.
Blood Advances|August 12, 2024
Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALLColleen Annesley, Adam Lamble, Corinne Summers, et al.
Blood|November 8, 2019
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyRebecca A Gardner, Francesco Ceppi, Julie Rivers, et al.
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Blood|November 19, 2024
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaMonica S Nair, Sara K Silbert, Kai Rejeski, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Blood|April 15, 2017
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsRebecca A Gardner, Olivia Finney, Colleen Annesley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) StudyTodd M Cooper, Jeannette Cassar, Elena Eckroth, et al.
Blood|April 15, 2025
Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALLColleen Annesley, Kristy D Seidel, Qian Wu, et al.
Cancer Immunology Research|May 17, 2022
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult SubjectsFrancesco Ceppi, Ashley L Wilson, Colleen Annesley, et al.
Pageof 3